Incorporation of liver chemistry score in predicting survival of liver-involved advanced gastric cancer patients who received palliative chemotherapy

被引:4
|
作者
Feng, Ying [1 ]
Zhang, Cheng [1 ,2 ]
Wu, Zhijun [3 ]
Xu, Hui [1 ,2 ]
Zhang, Xiaopeng [4 ]
Feng, Chong [4 ]
Shao, Jingyi [1 ]
Xie, Minmin [1 ]
Yang, Yahui [1 ]
Zhang, Yi [1 ]
Ma, Tai [1 ]
机构
[1] Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China
[2] Anhui Prov Canc Inst, Anhui Prov Off Canc Prevent & Control, Hefei, Peoples R China
[3] Maanshan Municipal Peoples Hosp, Dept Oncol, Maanshan, Peoples R China
[4] Hefei Ctr Dis Control & Prevent, Dept Noncommunicable Dis & Hlth Educ, Hefei, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 03期
关键词
gastric cancer; liver function tests; liver metastasis; survival analysis; PHASE-III; PROGNOSTIC-FACTORS; FUNCTION TESTS; CISPLATIN; TRIAL; MODEL; MULTICENTER; S-1;
D O I
10.1002/cam4.5179
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Gastric cancer liver metastasis (GCLM) patients usually accompany by abnormal serum liver function tests (LFTs) more or less; however, the prognostic value of LFTs is not fully understood. This study aimed to develop a liver chemistry score (LCS) based on LFTs and incorporate it into prognosis determination for GCLM patients who received palliative chemotherapy. Methods Data were derived from hospitalized GCLM patients in two general hospitals in China. LCS was generated based on the results of LFTs by LASSO regression. Cutoff value of the score was determined by restricted cubic spline. The score was then incorporated into Cox regression analysis to construct a predictive nomogram; the model was then evaluated internally and externally by AUC of time-dependent receiver operating characteristic curves (ROC) and calibration curves. Results Three hundred and thirty-six and 72 patients were included in development and validation cohort, respectively. LASSO regression analysis in development cohort finally reached a two-parametric LCS calculated on AST and ALP levels as 0.03343515 x ln (AST, U/L) + 0.02687997 x ln (ALP, U/L), and 0.232 was set as optimal cutoff value. Patients in low (LCS < 0.232) or high (LCS >= 0.232) score group experienced different survival times; median OS was 13.54 (95% CI: 11.1-15.6) months in the low LCS group and 7.3 (6.6-9.3) months in the high LCS group (p < 0.001). A nomogram including LCS and other clinical parameters was constructed and showed superior performance than model not including LCS. AUC of 6-month ROC improved from 0.647 (95% CI: 0.584-0.711) to 0.699 (0.638-0.759) in internal validation, and 0.837 (0.734-0.940) to 0.875 (0.784-0.966) in external validation. Conclusions Liver chemistry score is useful in determining the prognosis of gastric cancer patients with liver metastasis and may be helpful to clinicians in decision-making.
引用
收藏
页码:2831 / 2841
页数:11
相关论文
共 50 条
  • [41] Predicting survival in locally advanced gastric cancer using prognostic factors - neoadjuvant rectal score and downstaging depth score
    Tamam, S.
    Culcu, S.
    Eroezkan, K.
    Benk, Ms
    Azili, C.
    Altinsoy, E.
    Ersoz, S.
    Unal, Ae
    SOUTH AFRICAN JOURNAL OF SURGERY, 2024, 62 (01) : 72 - 79
  • [42] A risk score for the prognosis prediction of the muscle-invasive bladder cancer patients who received gemcitabine plus cisplatin chemotherapy
    Guo, Yupeng
    Dong, Jing
    Ji, Tao
    Li, Xiaoxia
    Rong, Shengzhong
    Guan, Hongjun
    AGING-US, 2022, 14 (23): : 9715 - 9729
  • [43] Identifying Optimal Surgical Intervention-Based Chemotherapy for Gastric Cancer Patients With Liver Metastases
    Sun, Min
    Ding, Hangliang
    Zhu, Zhiqiang
    Wang, Shengsheng
    Gu, Xinsheng
    Xia, Lingyun
    Li, Tian
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [44] Advanced Gastric Cancer with Liver and Lymph Node Metastases Successfully Resected after Induction Chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil
    Cavanna, Luigi
    Bodini, Flavio Cesare
    Stroppa, Elisa Maria
    Banchini, Filippo
    Michieletti, Emanuele
    Capelli, Patrizio
    Zangrandi, Adriano
    Anselmi, Elisa
    CHEMOTHERAPY, 2014, 60 (04) : 224 - 227
  • [45] The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy
    Kazuki Kano
    Toru Aoyama
    Yukio Maezawa
    Tetsushi Nakajima
    Kosuke Ikeda
    Takanobu Yamada
    Tsutomu Sato
    Takashi Oshima
    Yasushi Rino
    Munetaka Masuda
    Takashi Ogata
    Haruhiko Cho
    Takaki Yoshikawa
    International Journal of Clinical Oncology, 2017, 22 : 887 - 896
  • [46] A Retrospective Comparison of Docetaxel and Paclitaxel for Patients with Advanced or Recurrent Esophageal Cancer Who Previously Received Platinum-Based Chemotherapy
    Mizota, Ayako
    Shitara, Kohei
    Kondo, Chihiro
    Nomura, Motoo
    Yokota, Tomoya
    Takahari, Daisuke
    Ura, Takashi
    Muro, Kei
    ONCOLOGY, 2011, 81 (3-4) : 237 - 242
  • [47] Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy
    Graziano, Francesco
    Ruzzo, Annamaria
    Canestrari, Emanuele
    Catalano, Vincenzo
    Santini, Daniele
    Galluccio, Nadia
    Loupakis, Fotios
    Alessandroni, Paolo
    Spada, Daniele
    Ficarelli, Rita
    Bisonni, Renato
    D'Emidio, Silvia
    Vincenzi, Bruno
    Angeletti, Silvia
    Salvatore, Lisa
    Cremolini, Chiara
    Tonini, Giuseppe
    Falcone, Alfredo
    PHARMACOGENOMICS, 2010, 11 (09) : 1247 - 1256
  • [48] Patients with recurrent biliary tract cancer have a better prognosis than those with unresectable disease: retrospective analysis of a multi-institutional experience with patients of advanced biliary tract cancer who received palliative chemotherapy
    Ikezawa, Kenji
    Kanai, Masashi
    Ajiki, Tetsuo
    Tsukamoto, Tadashi
    Toyokawa, Hideyoshi
    Terajima, Hiroaki
    Furuyama, Hiroaki
    Nagano, Hiroaki
    Ikai, Iwao
    Kuroda, Nobukazu
    Awane, Masaaki
    Ochiai, Toshiya
    Takemura, Shigekazu
    Miyamoto, Atsushi
    Kume, Makoto
    Ogawa, Masao
    Takeda, Yutaka
    Taira, Kaoru
    Ioka, Tatsuya
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2014, 21 (02) : 98 - 104
  • [49] Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer
    Shitara, Kohei
    Matsuo, Keitaro
    Muro, Kei
    Doi, Toshihiko
    Ohtsu, Atsushi
    GASTRIC CANCER, 2014, 17 (02) : 362 - 370
  • [50] The Memorial Sloan Kettering Prognostic Score: Correlation with survival in patients with advanced gastric cancer
    Wan, Mingyu
    Ding, Yongfeng
    Ma, Xiaolu
    Chen, Xiaoyu
    Xu, Xin
    Mao, Chenyu
    Qian, Jiong
    Xiao, Cheng
    Jiang, Haiping
    Zheng, Yulong
    Teng, Lisong
    Xu, Nong
    CANCER MEDICINE, 2023, 12 (19): : 19656 - 19666